Lisa A. Prosser, Ph.D., M.S.
Associate Professor, Department of Pediatrics and Communicable Diseases
Dr. Prosser's research focuses on measuring the comparative effectiveness and cost-effectiveness of childhood health interventions using methods of decision sciences and economics. Current research topics include evaluating long-term health and economic outcomes for newborn screening programs using simulation modeling, measuring public values for screening programs, and developing new methods for valuing family spillover effects of childhood illness.
Dr. Prosser's applied research on the economic impact of influenza vaccination has been used in setting national vaccine policy for children and for prioritizing subgroups in vaccine shortage years. Research using decision science modeling to project long-term health outcomes for proposed newborn screening programs have been used to inform national newborn screening policy decisions. Her methodological research focuses on evaluation and development of methods for valuing child health benefits for cost-effectiveness analysis and for incorporating family spillover effects on quality-of-life for childhood illnesses. A current project is testing new approaches for valuing family spillover effects on health-related quality of life for caregivers who have family members with a chronic health condition using both qualitative and quantitative methods.
She is a member of the evidence review group for the Advisory Committee on Heritable Disorders in Newborns and Children. Dr. Prosser was the founding decision scientist for the Institute for Clinical and Economic Review. Dr. Prosser also holds adjunct faculty appointments at Harvard Medical School and the Harvard School of Public Health.
Ph.D., Health Policy (Concentration: Decision Sciences), Harvard University, 2000
M.S., Technology & Policy, Massachusetts Institute of Technology, 1992
M.S., Management, MIT Sloan School of Management, 1992
B.A., Mathematics (Concentration: Operations Research), Cornell University, 1988
Evidence of spillover of illness among household members: EQ-5D scores from a US sample.
Med Decis Making. In press.
Associations between physician financial incentives and prescribing of anti‐Asthmatic medications in children in US outpatient settings.
Journal of Child Health. In press.
Ulnar neuropathy at the elbow: A cost-utility analysis.
J Hand Surg. 2012;37(8):1617-1629.e3.
Comparative effectiveness and child health.
PharmacoEconomics. 2012; 30(8):637-45.
Decision analysis, economic evaluation, and newborn screening: Challenges and opportunities.
Genet Med. 2012; doi: 10.1038/gim.2012.24. [Epub ahead of print]
Parental and societal values for the risks and benefits of childhood combination vaccines.
Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus vaccine.
Health-related quality of life in adolescents with or at risk for Type 2 diabetes mellitus.
J Pediatr. 2012;160(6):911-7.
Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus.
Diab Med. 2012;29(4):453-63.
Health utility elicitation: Is there still a role for direct methods?
PharmacoEconomics. 2012; Feb 1; 30(2):83-6.
Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza.
J Pediatr. 2012;160(1):67-73
Seasonal influenza vaccination of healthy, working-age adults: A review of economic evaluations.
Drugs. 2012 Jan 1;72(1):35-48.
Community-based values for 2009 pandemic influenza A (H1N1) illnesses and vaccination-related adverse events.
PLoS ONE. 6(12):e27777.doi:10.1371/journal.pone.0027777
Cost-effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States.
PLoS ONE. 2011;6(7):e22308. Epub 2011 Jul 29.
Preferences for type 2 diabetes health states among adolescents with or at risk of type 2 diabetes mellitus.
Pediatric Diabetes. 2011 Apr 13. doi: 10.1111/j.1399-5448.2011.00772.x. [Epub ahead of print]
Randomized controlled trial to improve primary care to prevent and manage childhood obesity: the High Five for Kids study.
Arch Pediatr Adolesc Med. 2011 Aug;165(8):714-22. Epub 2011 Apr 4.
Ordering errors, objections and invariance in utility survey responses: a framework for understanding who, why and what to do.
Appl Health Econ Health Policy. 2011;9(4):225-41.
Valuing health at different ages: evidence from a nationally representative survey in the United States.
Appl Health Econ Health Policy. 2011;9(3):149-56.
Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years.
Arch Pediatr Adolesc Med. 2011;165(2):112-8.
Health state preferences associated with weight status in children and adolescents.
BMC Pediatrics. 2011:11(1):12.
Effectiveness and cost-effectiveness of blood pressure screening in adolescents in the United States.
J Pediatr. 2011;158(2):257-64.
Valuing health across the lifespan: health state preferences for seasonal influenza illnesses in patients of different ages.
Value Health. 2011;14(1):135-43.
An evidence development process for newborn screening.
Genet Med. 2010;12(3):131-134.
QALY weights for neurosensory impairments in pediatric economic evaluations: Case studies and a critique.
Expert Review of Pharmacoeconomics & Outcomes Research. 2010;10(3): 293-308.
Use of outcomes-weighted ROC curves to evaluate surveillance systems for bioterrorist attacks.
BMC Med Inform Decis Mak. 2010;10:1-11.
A systematic review of the evidence for newborn screening and treatment of severe combined immunodeficiency.
Projected costs, risks, and benefits of expanded newborn screening for MCADD.
Economic and other barriers to adopting recommendations to prevent childhood obesity: results of a focus group study with parents.
BMC Pediatrics. 2009;9(81):1-21.
Willingness-to-pay for a quality-adjusted life-year based on community member and patient preferences for temporary health states associated with zoster.
PharmacoEconomics. 2009; 27(12): 1005-16.
Impact of false-positive newborn metabolic screening results on early health care utilization.
Genet Med. 2009; 11(10):1-6.
Methods for measuring temporary health states for cost-utility analyses (review).
PharmacoEconomics. 2009; 27(9): 713-23.
Current challenges and future research in measuring preferences for pediatric health outcomes (invited editorial).
J Pediatr. 2009;155(1):7-9.
New vaccines against otitis media: projected benefits and cost-effectiveness.
Parental tolerance for false-positive newborn screening results.
Arch Pediatr Adolesc Med. 2008;162(9):870-6.
Community and patient values for preventing zoster.
Projected cost-effectiveness of new vaccines for adolescents in the United States (review).
Pediatrics.2008;121 Suppl 1:S63-78.
Non-traditional settings for influenza vaccination of adults: Costs and cost-effectiveness.
Valuing children’s health: a comparison of cost-utility analyses for adult and pediatric health interventions (review).
Measuring health preferences for use in cost-utility and benefit analyses of interventions in children: Theoretical and methodological considerations.
Do risk attitudes differ across domains and respondent types?
Med Decis Making. 2007;27(3):281-287.
Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications.
J Clin Hyper. 2007;9(1):15-20.
Measuring health-related quality of life for child maltreatment: A systematic literature review.
Health Qual Life Outcomes. 2007;5(1)1-17. Available at: http://www.hqlo.com/content/5/1/42.
Health benefits, risks, and cost-effectiveness of influenza vaccination of children.
Emerg Infect Dis. 2006;12(10):1548-1558.
Clinical and non-clinical correlates of adherence to prescribing guidelines for hypertension in a large managed care organization.
J Clin Hypertension. 2006;8(6):414-419.
The effect of age, race and gender on preference scores for hypothetical health states.
Qual Life Res. 2006;15(4):645-653.
Predictors of hospital charges for children admitted with asthma.
Ambul Pediatr. 2006;6(1):15-20.
Values for preventing influenza-related morbidity and vaccine adverse events in children.
Health Qual Life Outcomes. 2005;3(18):1-16.
Comments on the Prosser et al approach to value disease reduction in children: In reply (letter).
Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.
A cost-benefit analysis of electronic medical records in primary care.
Am J Med. 2003;114(5):397-403.
Patient and community preferences for treatments and health states in multiple sclerosis.
Mult Scler. 2003;9:311-319.
Emerging issues in vaccine economics: perspectives from the USA.
Expert Rev Vaccines. 2002:1(4):433-442.
The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis.
Med Decis Making. 2002;22:506-513.
Cost-effectiveness analyses (letter).
Ann Intern Med 2001;135(5):383.
Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Ann Intern Med. 2000;132(10):768-779.
Barriers to using cost-effectiveness analysis in managed care decision making.
Am J Manag Care. 2000;6(2):173-179.